Please try another search
Symbol | Exchange | Currency | ||
---|---|---|---|---|
PSYBh | CBOE Canada | CAD | Real-time | |
PSYBh | TSXV | CAD | Delayed |
For the three months ended 31 March 2022, Psybio Therapeutics Corp revenues was not reported. Net loss decreased 39% to $1.6M. Lower net loss reflects Listing expense decrease from $1.2M (expense) to $0K, Consulting fees decrease of 96% to $26K (expense), Other income increase from $1K to $11K (income). Basic Earnings per Share excluding Extraordinary Items increased from -$0.03 to -$0.01.
Period Ending: | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 |
---|---|---|---|---|
Total Revenue | 0 | 0 | 0 | 0 |
Gross Profit | ||||
Operating Income | -1.48 | -2.22 | -2.3 | -3.76 |
Net Income | -1.59 | -2.28 | -2.3 | -3.76 |
Period Ending: | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 |
---|---|---|---|---|
Total Assets | 2.84 | 4.01 | 6.55 | 8.01 |
Total Liabilities | 1.44 | 1.29 | 1.71 | 1.67 |
Total Equity | 1.4 | 2.72 | 4.83 | 6.33 |
Period Ending: | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 |
---|---|---|---|---|
Period Length: | 3 Months | 12 Months | 9 Months | 9 Months |
Cash From Operating Activities | -1.26 | -6.95 | -4.67 | -3.14 |
Cash From Investing Activities | 1.29 | -3.56 | -5.61 | -7.15 |
Cash From Financing Activities | -0.05 | 10.37 | 10.55 | 10.55 |
Net Change in Cash | -0.02 | -0.15 | 0.24 | 0.08 |
Unlock access to over 1000 metrics with InvestingPro
View advanced insights on financial statements, including growth rates and metrics that provide an in-depth view of the company's historical and forecasted financial performance.
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review